Edgen Stock·Dec 11 2025, 17:04Back
FDA Expedites Bristol Myers' Hodgkin Lymphoma Drug Review
Edgen Stock·Dec 11 2025, 17:04
[1] First Commissioner’s Priority Review Approval Goes to Decades-Old Antibiotic - biospace.com (https://www.biospace.com/fda/first-commission ...)[2] First Commissioner’s Priority Review Approval Goes to GSK’s Decades-Old Antibiotic - BioSpace (https://www.biospace.com/fda/first-commission ...)[3] Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL - BioSpace (https://www.biospace.com/press-releases/lilly ...)
